An industrial equipment manufacturer came to us with an enclosure design that had been developed on solid modeling software by an engineer whose previous experience was almost entirely in machined components.
A product team was twelve weeks from a clinical submission deadline. They needed thirty units of a handheld medical device housing, production-representative in cosmetics, dimensionally accurate, and available in two colorways for user testing.
A consumer electronics company came to us with a housing part they had been machining at low volume while they waited on market validation.
Picture a part that has been through weeks of engineering review. The 3D model is solid. Wall thicknesses have been checked, tolerances have been assigned, and the geometry looks exactly the way it needs to function.
The quote came in at $12,000. The domestic option was $49,000. For a medical device manufacturer under budget pressure, the math looked obvious – until the tool arrived.
The product manager’s spreadsheet said injection molding was cheaper. It was – on a per-part basis. What the spreadsheet didn’t include was the $18,000 steel mold, the six-week lead time.
The design passed DVT. The contract manufacturer had been briefed. The steel mold was quoted. And then someone on the leadership team asked when they could start shipping.
The part passed every test. Eight months of iteration, four rounds of DVT, a signed-off design review. The first production run shipped 400 units. Thirty percent came back.
The medical device startup had 60 days to get functional housings into the hands of a clinical partner. Their enclosure design was largely validated – one or two minor tweaks still possible, but nothing structural.
A product manager at a consumer electronics company recently landed a pilot order: 1,200 units of a plastic enclosure, confirmed purchase order, ship date in eight weeks.
A medical device company completes a successful pilot. The manufacturing process looks clean, the assembly line is humming, and the launch timeline is on track – until field returns start coming in at month four.
The engineering team celebrated. Their medical device prototype worked perfectly, passed initial testing, and impressed investors. Early manufacturing decisions looked solid.
The product manager had 72 hours to decide. His startup needed 500 housings for beta units shipping to pilot customers next month.
The call came at 4 PM on a Friday. A Tier 1 automotive supplier’s injection molding resin vendor couldn’t deliver next week’s order. Force majeure.
A product manager at a medical device company got the call on a Tuesday morning. Their primary resin supplier declared force majeure. Production stopped.
A medical device startup spent eight months perfecting their prototypes. The design won awards. Investors lined up. Then they scaled to production, and the failure rate hit 40 percent.
When selecting the manufacturing process for functional prototypes or low-volume production, the decision can often feel overwhelming.
The production line was ready. Materials were in. Demand was real. Then a single tool cracked.
The first prototype looked perfect on screen. Clean geometry. Tight tolerances. Everyone nodded in the review.
In early 2020, a mid-sized molding supplier in Eastern Europe found itself in an unforeseen crisis.
In Silicon Valley, a product team racing against time had their prototype ready but something was wrong.
The part looked right on the screen. It cleared internal review. It even passed a quick Design For Manufacturing (DFM) check.
Rapid Prototyping Is No Longer a Safety Net. It’s the Critical Path.
